Science Explorer Back to mapMap
Discussion
Company · Montpellier · France

Surgimab (France)

surgimab.comROR OpenAlex
Research works
6
▼ 17% vs 2018-21
Citations
114
20.2 per fractional work
Top-10% rate
1.6%
all institutions 10.0%
Open access
42%
world 40%
International
65%
world 18%
Surgimab (France)

Not ranked overall: Surgimab (France) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Surgimab (France) work in?

In all years, 44% of research at Surgimab (France) is in Health Sciences, 36% in Life Sciences. Its largest fields are Medicine (44%), Biochemistry, Genetics and Molecular Biology (35%), Engineering (18%). It does 1.3× the world's share of Life Sciences.

Health Sciences: 2 fractional works · 44.4% of its workMedicine: 2 fractional works · 44.4% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 10.5% of its workPulmonary and Respiratory Medicine: 0 fractional works · 8.3% of its workOncology: 0 fractional works · 7.1% of its workSurgery: 0 fractional works · 5.0% of its workNeurology: 0 fractional works · 4.1% of its workReproductive Medicine: 0 fractional works · 3.4% of its workPsychiatry and Mental health: 0 fractional works · 3.0% of its workHepatology: 0 fractional works · 2.1% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.9% of its workLife Sciences: 2 fractional works · 35.9% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 35.3% of its workBiotechnology: 1 fractional works · 21.8% of its workMolecular Biology: 1 fractional works · 11.2% of its workCell Biology: 0 fractional works · 1.6% of its workGenetics: 0 fractional works · 0.7% of its workNeuroscience: 0 fractional works · 0.5% of its workNeurology: 0 fractional works · 0.5% of its workPhysical Sciences: 1 fractional works · 19.7% of its workEngineering: 1 fractional works · 17.9% of its workBiomedical Engineering: 1 fractional works · 17.9% of its workMaterials Science: 0 fractional works · 1.8% of its workBiomaterials: 0 fractional works · 1.8% of its workALL ITS WORKSurgimab (France)6fractional works, all years
Life Sciences36%Physical Sciences20%Health Sciences44%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 5 fields, with their numbers
    1. Medicine244.4%
    1. Biochemistry, Genetics and Molecular Biology235.3%
    2. Neuroscience00.5%
    1. Engineering117.9%
    2. Materials Science01.8%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Who are the top researchers at Surgimab (France)?

Ranked on the quality score, Bérénice Framery and Françoise Cailler lead among researchers whose main affiliation is Surgimab (France).

  1. 1 Bérénice Framery France · #975,511 worldwide 733 citations · 26 works
  2. 2 Françoise Cailler France · #1,433,099 worldwide 1k citations · 44 works
All ranked researchers at Surgimab (France)

What are the most cited papers from Surgimab (France)?

The most cited paper from Surgimab (France) is "Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study" (Leonora S. F. Boogerd et al., 2018), with 202 citations. Next come "Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent" (155) and "SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery" (115).

Most cited papers
#PaperReleasedCitations
1 Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study Leonora S. F. Boogerd et al. · ˜The œLancet. Gastroenterology & hepatology Open access 30 Jan 2018 202
2 Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent Charlotte E.S. Hoogstins, Leonora S. F. Boogerd, Babs G. Sibinga Mulder et al. · Annals of Surgical Oncology Open access 26 Jul 2018 155
3 SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery Marian Gutowski, Bérénice Framery, Martin C. Boonstra et al. · Surgical Oncology Open access 9 Mar 2017 115
4 Dose-Finding Study of a CEA-Targeting Agent, SGM-101, for Intraoperative Fluorescence Imaging of Colorectal Cancer Kim S. de Valk, Marion M. Deken, Dennis P. Schaap et al. · Annals of Surgical Oncology Open access 9 Oct 2020 79
5 Carcinoembryonic antigen-specific, fluorescent image-guided cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer Dennis P. Schaap et al. · British journal of surgery Open access 21 Jan 2020 60
All 23 most cited papers, with filters and sorting

Which research topics does Surgimab (France) publish most on?

By volume in 2022-now: Cancer Research and Treatments, Angiogenesis and VEGF in Cancer, Nanoplatforms for cancer theranostics and Gastric Cancer Management and Outcomes.

Cancer Research and Trea…1Cancer Research and Treatments: 1 fractional worksAngiogenesis and VEGF in…0Angiogenesis and VEGF in Cancer: 0 fractional worksNanoplatforms for cancer…0Nanoplatforms for cancer theranostics: 0 fractional worksGastric Cancer Managemen…0Gastric Cancer Management and Outcomes: 0 fractional worksNeurological disorders and treatments: 0 fractional worksBotulinum Toxin and Related Neurological Disorders: 0 fractional worksGlycosylation and Glycoproteins Research: 0 fractional worksCancer Cells and Metastasis: 0 fractional worksMonoclonal and Polyclonal Antibodies Research: 0 fractional worksHepatocellular Carcinoma Treatment and Prognosis: 0 fractional works
BiotechnologyMolecular BiologyBiomedical EngineeringPulmonary and Respiratory Medicine4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Cancer Research and Treatments Biotechnology 1 works
  2. 2 Angiogenesis and VEGF in Cancer Molecular Biology 0 works
  3. 3 Nanoplatforms for cancer theranostics Biomedical Engineering 0 works
  4. 4 Gastric Cancer Management and Outcomes Pulmonary and Respiratory Medicine 0 works
  5. 5 Neurological disorders and treatments Neurology 0 works
  6. 6 Botulinum Toxin and Related Neurological Disorders Neurology 0 works
  7. 7 Glycosylation and Glycoproteins Research Molecular Biology 0 works
  8. 8 Cancer Cells and Metastasis Oncology 0 works
  9. 9 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  10. 10 Hepatocellular Carcinoma Treatment and Prognosis Hepatology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available41.6%not open58.4%

World: 40% of research is openly available.

with international co-authors65.1%domestic only34.9%

World: 18% is written across borders.

How has Surgimab (France)'s research output changed?

Output in 2022-2025 was 17% lower than in 2018-2021.

still counting20202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Montpellier

All research institutions in Montpellier

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Surgimab (France). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.